Wedbush downgraded Vigil Neuroscience (VIGL) to Neutral from Outperform with an $8 price target after Sanofi (SNY) agreed to acquire Vigil for an upfront payment of $8.00 per share of common stock in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIGL:
- Vigil Neuroscience Enters Merger Agreement with Sanofi
- Vigil Neuroscience downgraded to Neutral from Buy at Guggenheim
- Vigil Neuroscience downgraded to Market Perform from Outperform at William Blair
- Vigil Neuroscience downgraded to Market Perform from Outperform at Citizens JMP
- Vigil Neuroscience to be acquired by Sanofi for $8.00 per share